Brown Remodeling of White Adipose Tissue by PPARgamma Deacetylation

PPARgamma 脱乙酰化对白色脂肪组织的棕色重塑

基本信息

  • 批准号:
    9329411
  • 负责人:
  • 金额:
    $ 24.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-17 至 2018-09-16
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal describes a five-year plan for Li Qiang to transition to an independently-funded investigator, applying rigorous scientific method to metabolic research. Dr. Qiang received PhD degree from Boston University School of Medicine in 2007 and performed postdoctoral training in Diabetes Research Center (DRC) and Department of Medicine at Columbia University since 2008. Dr. Qiang's training cemented his intent to uncover the browning mechanism of white adipose tissue (WAT) through Pparγ deacetylation, and further lead to the discovery of novel therapeutic agent to treat metabolic syndrome. The goals of the proposed training are to provide training and mentoring to prepare Dr. Qiang for an independent research career, and additionally, to answer fundamental questions that persist in obesity research and how it goes awry in diabetic patients. Obesity leads to insulin resistance and further Type 2 diabetes. Currently available insulin sensitizer thiazolidinediones (TZDs) are at skepticism for their detrimental effects. Recently browning of WAT has been appreciated for its metabolic improvement. A mechanistic understanding of the browning function of TZD is necessary to develop new anti-diabetic drugs that are shorn of the side effects. In this application, Dr. Qiang describes preliminary data that reveal the novel role f acetylation in regulating the transcriptional selectivity of Pparγ. Dr. Qiang and one of his mentors, Domenico Accili, determined that SirT1 gain-of-function mimics TZD in browning WAT. These effects were recapitulated by the deacetylation-mimetic Pparγ-2KR mutant in vitro. Dr. Qiang proposes in this application (1) to characterize the physiological significance of Pparγ deacetylation, (2a) to determine the mechanism by which Pparγ deacetylation converts energy-storing WAT into energy-dissipating BAT-like tissue, and (2b) to study the interplay between acetylation and other post-translational modifications (PTMs) in regulating Pparγ's transcriptional selectivity and metabolic functions. The results gained from these proposed studies should yield important insights into whether reprogramming white adipose tissue into an energy-dispersal site will provide new treatment options for human obesity and diabetes, and whether it is possible to develop a new class of Pparγ ligands that displays TZD's beneficial metabolic effects but without its cardiovascular, oncogenic, and bone loss comorbidities. Dr. Qiang's long-term career objective is to understand the mechanisms of brown remodeling WAT through PTMs of Pparγ, and further translate the seminal discoveries made at the bench into therapeutic treatments for obesity and diabetes. The scientific knowledge that required to integrate browning WAT at both molecular level and physiological level, as well as in the many complicated and technical aspects of Pparγ PTMs and SirT1 biology, can best be addressed through his choice of mentors (Drs. Domenico Accili and Wei Gu) and collaborators (Drs. Ira Goldberg and Yingming Zhao), all respected investigators who value mentoring young and aspiring faculty members. Finally, the Columbia University Medical Center environment brings together access to a diverse metabolic research groups and all the facilities and faculty developmental tools that Dr. Qiang will need in order to become an independent investigator and a productive member of the academic metabolism community.
内容(由申请人提供):本提案描述了李强向独立科研人员过渡的五年计划,将严格的科学方法应用于代谢研究。2007年获波士顿大学医学院博士学位,2008年起在哥伦比亚大学糖尿病研究中心(DRC)和医学部进行博士后培训。Qiang博士的训练巩固了他通过Pparγ去乙酰化揭示白色脂肪组织(WAT)褐变机制的意图,并进一步导致发现治疗代谢综合征的新型药物。拟议培训的目标是为Qiang博士提供培训和指导,为独立的研究生涯做好准备,此外,回答肥胖研究中持续存在的基本问题,以及它如何在糖尿病患者中出错。肥胖会导致胰岛素抵抗和进一步的2型糖尿病。目前可用的胰岛素增敏剂噻唑烷二酮(TZDs)因其有害作用而受到怀疑。最近褐化的WAT因其改善代谢而受到重视。了解TZD褐变功能的机制,对于开发减少其副作用的新型抗糖尿病药物是必要的。在这一应用中,Qiang博士描述了初步数据,揭示了乙酰化在调节Pparγ转录选择性中的新作用。Qiang博士和他的导师之一Domenico Accili确定SirT1的功能获得与TZD在褐化WAT中的相似。这些效应在体外模拟去乙酰化的Pparγ-2KR突变体中得到了再现。Qiang博士在本申请中提出(1)表征Pparγ去乙酰化的生理意义,(2a)确定Pparγ去乙酰化将储存能量的WAT转化为耗散能量的bat样组织的机制,(2b)研究乙酰化和其他翻译后修饰(PTMs)在调节Pparγ转录选择性和代谢功能中的相互作用。从这些提议的研究中获得的结果应该对重新编程白色脂肪组织为能量分散位点是否会为人类肥胖和糖尿病提供新的治疗选择提供重要的见解,以及是否有可能开发一类新的Pparγ配体,显示TZD的有益代谢作用,但没有其心血管,致癌和骨质流失合并症。Qiang博士的长期职业目标是通过Pparγ的PTMs了解褐色重塑WAT的机制,并进一步将在实验台上取得的开创性发现转化为肥胖和糖尿病的治疗方法。在分子水平和生理水平上整合褐变WAT所需的科学知识,以及在Pparγ PTMs和SirT1生物学的许多复杂和技术方面,可以通过他选择的导师(dr。Domenico Accili和Wei Gu)及其合作者(dr .。Ira Goldberg和Yingming Zhao),他们都是受人尊敬的研究者,重视指导年轻而有抱负的教师。最后,哥伦比亚大学医学中心的环境汇集了不同的代谢研究小组和所有的设施和教师发展工具,强博士将需要成为一个独立的研究者和学术代谢社区的富有成效的成员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Li Qiang其他文献

A KIND OF GENERALIZED TRANSVERSALITY THEOREM FOR C-r MAPPING WITH PARAMETER
一种带参数C-r映射的广义横截定理

Li Qiang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Li Qiang', 18)}}的其他基金

Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment
PPARg 乙酰化抑制剂预防和治疗糖尿病的临床前验证
  • 批准号:
    10430186
  • 财政年份:
    2021
  • 资助金额:
    $ 24.9万
  • 项目类别:
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment
PPARg 乙酰化抑制剂预防和治疗糖尿病的临床前验证
  • 批准号:
    10225150
  • 财政年份:
    2021
  • 资助金额:
    $ 24.9万
  • 项目类别:
PPARgamma Deacetylation in the Restoration of Metabolic Homeostasis
PPARgamma 脱乙酰化在恢复代谢稳态中的作用
  • 批准号:
    10182582
  • 财政年份:
    2017
  • 资助金额:
    $ 24.9万
  • 项目类别:
PPARgamma Deacetylation in the Restoration of Metabolic Homeostasis
PPARgamma 脱乙酰化在恢复代谢稳态中的作用
  • 批准号:
    10302265
  • 财政年份:
    2017
  • 资助金额:
    $ 24.9万
  • 项目类别:
PPARgamma Deacetylation in the Restoration of Metabolic Homeostasis
PPARgamma 脱乙酰化在恢复代谢稳态中的作用
  • 批准号:
    10064620
  • 财政年份:
    2017
  • 资助金额:
    $ 24.9万
  • 项目类别:
Brown Remodeling of White Adipose Tissue by PPARgamma Deacetylation
PPARgamma 脱乙酰化对白色脂肪组织的棕色重塑
  • 批准号:
    9145652
  • 财政年份:
    2015
  • 资助金额:
    $ 24.9万
  • 项目类别:
Brown Remodeling of White Adipose Tissue by PPARgamma Deacetylation
PPARgamma 脱乙酰化对白色脂肪组织的棕色重塑
  • 批准号:
    9121141
  • 财政年份:
    2015
  • 资助金额:
    $ 24.9万
  • 项目类别:
Brown Remodeling of White Adipose Tissue by PPARgamma Deacetylation
PPARgamma 脱乙酰化对白色脂肪组织的棕色重塑
  • 批准号:
    8717658
  • 财政年份:
    2013
  • 资助金额:
    $ 24.9万
  • 项目类别:
Brown Remodeling of White Adipose Tissue by PPARgamma Deacetylation
PPARgamma 脱乙酰化对白色脂肪组织的棕色重塑
  • 批准号:
    8581242
  • 财政年份:
    2013
  • 资助金额:
    $ 24.9万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了